SEC Form 4 · accession 0001849739-26-000014
ImmunityBio, Inc. · IBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christobel Selecky
Director
Period of report
Jul 1, 2026
Accepted (ET)
Jul 6, 2026 · 8:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001326110
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2026 | M | 35,064 | $2.98 | A | 35,064 | D | |
| Common Stock | Jul 1, 2026 | M | 124,414 | $2.99 | A | 159,478 | D | |
| Common StockF2 | Jul 1, 2026 | S | 159,478 | $9.0236 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $2.98 | Jul 1, 2026 | M | 35,064 | D | Jun 12, 2023 | Jun 14, 2032 | Common Stock | 35,064 | 0 | D |
| Stock Option (right to buy) | $2.99 | Jul 1, 2026 | M | 124,414 | D | Jun 10, 2024 | Jun 13, 2033 | Common Stock | 124,414 | 0 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
- F2Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.